NK - NantKwest, Inc.
| Previous Close | 1.7300 |
| Open | 1.7200 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.7000 - 1.9500 |
| 52 Week Range | 0.9300 - 1.9900 |
| Volume | 320,526 |
| Avg. Volume | 182,690 |
| Market Cap | 189M |
| Beta (3Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7550 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.25 |
- Benzinga
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
- Business Wire
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
NantKwest, Inc. (NK), a clinical-stage natural killer cell-based therapeutics company, today announced promising safety data generated from the first six patients in its QUILT-3.064 trial. The first-in-human study evaluated the safety and preliminary efficacy of the Company’s first-in-class, tumor-targeted PD-L1.t-haNK cell therapy in patients with locally advanced or metastatic solid tumors. “The unique dual-targeting of PD-L1.t-haNK to both PD-L1 expressing tumors and therapeutic monoclonal antibodies has the potential to be transformative to the treatment of advanced solid tumors with cell-based therapies,” said Dr. Patrick Soon-Shiong, the Chairman and CEO of NantKwest.
- TEST Business Wire Releases
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors
NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that on Monday, December 2, 2019, it will host a key opinion leader (KOL) meeting in New York City on the current treatment landscapes and unmet medical needs of patients with Merkel cell carcinoma, triple-negative breast cancer, solid tumors and the state-of-the-art treatment in the induction of Immunogenic Cell Death.
- Business Wire
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019
NantKwest Inc. (NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced the presentation of results from their Phase 2 trial investigation using aNK, NantKwest’s off-the-shelf natural killer cell-based therapeutic, in combination with N-803, ImmunityBio’s IL-15 superagonist, in patients with advanced refractory metastatic Merkel cell carcinoma (MCC) (NCT03853317) at The 34th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2019) on November 8, 2019 in National Harbor, Maryland. ImmunityBio is an affiliate company of NantKwest.
- Simply Wall St.
What Kind Of Shareholder Owns Most NantKwest, Inc. (NASDAQ:NK) Stock?
If you want to know who really controls NantKwest, Inc. (NASDAQ:NK), then you'll have to look at the makeup of its...
- Simply Wall St.
Does NantKwest, Inc.'s (NASDAQ:NK) CEO Pay Reflect Performance?
In 2015 Patrick Soon-Shiong was appointed CEO of NantKwest, Inc. (NASDAQ:NK). This report will, first, examine the CEO...
- Simply Wall St.
Who Has Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- Simply Wall St.
Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?
NantKwest, Inc. (NASDAQ:NK) shareholders should be happy to see the share price up 11% in the last month. But only the...
- Business Wire
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors
- Business Wire
Cheryl Cohen Appointed to NantKwest’s Board of Directors
NantKwest (Nasdaq:NK) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest, effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and pharmaceutical sectors,” said Patrick Soon-Shiong, Chairman and CEO of NantKwest. Since 2008, Ms. Cohen has served as president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization.
- Business Wire
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest (NK), a leading clinical-stage, natural killer cell based therapeutics company today presented a clinical data update in patients who have received off-the-shelf aNK and/or haNK natural killer cell therapy in combination with immunotherapeutic agents in advanced solid tumors.
- Business Wire
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
NantKwest Inc. (Nasdaq:NK) announced today that its strategic partner Viracta Therapeutics presented updated clinical data on its HDAC inhibitor, nanatinostat (VRx-3996) at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from May 31st – June 4th, 2019. In April 2017, NantKwest announced that it was the lead investor in Viracta’s Series B financing round. Concurrent with the financing, NantKwest secured an exclusive license with commercialization rights to nanatinostat for use in combination with natural killer (NK) cell therapies, including NantKwest’s NK cell platforms.
- Business Wire
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
NantKwest Inc. (NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that the company’s t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma.
- Business Wire
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019. The presentations and one-on-one discussions will feature a science/medicine review, along with a clinical update provided by Dr. Soon-Shiong and Company management.
- Business Wire
NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Inte
- Simply Wall St.
What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)?
The big shareholder groups in NantKwest, Inc. (NASDAQ:NK) have power over the company. Insiders often own a large...
- Business Wire
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
Brink Biologics, Inc., a NantKwest, Inc. (NK) affiliate who serves as exclusively-licensed distributor of NantKwest’s proprietary NK-92® natural killer cells, offers a variety of research grade aNK™ and haNK® cell lines for non-clinical laboratory use in discovery, translational and developmental research and lot release testing for commercial products ranging from monoclonal antibodies, bi-specific biologics, cytokines and other bioactive products.
- Business Wire
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
NantKwest (NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has been issued a new patent that further expands the Company’s foundational natural killer cell-therapeutics platform intellectual property estate. This new patent builds upon NantKwest’s extensive existing patent estate and broadens the Company’s established intellectual property combining haNK natural killer cell therapy together with antibody therapy.
- Zacks
Will NantKwest Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in NantKwest.
- Business Wire
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
NantKwest (NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company’s Chairman & CEO, on March 21, 2019, exercised 17,589,250 warrants with an exercise price of $1.9984 and 1,851,000 options with an exercise price of $2.1983, representing an aggregate cash exercise price of $39.2.
- Business Wire
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong, will be giving a keynote address at the Innate Killer Summit in San Diego on Wednesday, March 20, 2019. Dr. Soon-Shiong’s keynote address will provide a vision of next generation NK cell therapies and feature a review of translational R&D activities, state-of-the-art manufacturing requirements, along with clinical progress. “Over a few short years, the cell therapy industry has made significant progress with remarkable patient responses to therapy being seen in a few select cancer indications.
- Business Wire
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
NantKwest, Inc. (NK), a leading clinical-stage Natural Killer (NK) cell based therapeutics company, and ProMab Biotechnologies today announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with an option for up to five undisclosed targeting sequences for exclusive use in the development of chimeric antigen receptor (CAR) based NK cell therapies.
- Simply Wall St.
Our Take On NantKwest, Inc.’s (NASDAQ:NK) CEO Salary
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In 2015 Patrick Soon-Shiong was appointed CEO of NantKwest, Inc.Read More...
- Zacks
Is the Options Market Predicting a Spike in NantKwest (NK) Stock?
Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.
